IRIS
CALZETTA, Luigino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.143
NA - Nord America 8.509
EU - Europa 4.106
SA - Sud America 2.295
AF - Africa 636
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 7
Totale 25.717
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.237
SG - Singapore 4.548
VN - Vietnam 1.941
BR - Brasile 1.730
CN - Cina 1.240
IE - Irlanda 1.094
HK - Hong Kong 974
IT - Italia 666
SE - Svezia 487
BD - Bangladesh 482
ZA - Sudafrica 448
NL - Olanda 370
FR - Francia 369
DE - Germania 276
AR - Argentina 211
IN - India 208
RU - Federazione Russa 171
FI - Finlandia 169
GB - Regno Unito 125
AT - Austria 98
ID - Indonesia 98
CA - Canada 93
MX - Messico 93
IQ - Iraq 88
CO - Colombia 85
EC - Ecuador 73
PK - Pakistan 63
TR - Turchia 63
VE - Venezuela 59
JP - Giappone 49
CL - Cile 47
UA - Ucraina 43
EE - Estonia 38
MA - Marocco 38
PH - Filippine 38
PY - Paraguay 38
UZ - Uzbekistan 37
KR - Corea 36
TW - Taiwan 33
SA - Arabia Saudita 31
ES - Italia 30
PL - Polonia 29
CI - Costa d'Avorio 27
MY - Malesia 27
TH - Thailandia 27
BE - Belgio 25
PE - Perù 24
TN - Tunisia 22
KE - Kenya 21
AE - Emirati Arabi Uniti 20
EG - Egitto 19
AZ - Azerbaigian 18
IL - Israele 17
ET - Etiopia 15
JO - Giordania 15
LT - Lituania 15
BO - Bolivia 14
JM - Giamaica 14
AU - Australia 13
DZ - Algeria 13
PT - Portogallo 13
UY - Uruguay 13
DO - Repubblica Dominicana 12
KG - Kirghizistan 11
AL - Albania 10
HN - Honduras 10
OM - Oman 10
NI - Nicaragua 9
NP - Nepal 9
PS - Palestinian Territory 9
RS - Serbia 9
CH - Svizzera 8
HU - Ungheria 8
IR - Iran 8
AM - Armenia 7
CR - Costa Rica 7
KZ - Kazakistan 7
LB - Libano 7
NZ - Nuova Zelanda 7
RO - Romania 7
BG - Bulgaria 6
GT - Guatemala 6
HR - Croazia 6
PA - Panama 6
XK - ???statistics.table.value.countryCode.XK??? 6
BY - Bielorussia 5
PR - Porto Rico 5
SY - Repubblica araba siriana 5
BB - Barbados 4
BH - Bahrain 4
CZ - Repubblica Ceca 4
GR - Grecia 4
KW - Kuwait 4
LU - Lussemburgo 4
LY - Libia 4
NG - Nigeria 4
SN - Senegal 4
SV - El Salvador 4
AO - Angola 3
BW - Botswana 3
Totale 25.664
Salva come PNG Salva come JPEG
Città #
Singapore 2.120
Chandler 1.267
San Jose 1.264
Dublin 1.084
Ashburn 978
Hong Kong 935
Ho Chi Minh City 606
Santa Clara 467
Hanoi 438
Dallas 416
Johannesburg 416
Boardman 358
Lauterbourg 303
Beijing 282
Princeton 256
Helsinki 151
New York 148
Des Moines 145
Los Angeles 142
Munich 136
São Paulo 135
Rome 92
Haiphong 91
Wilmington 91
Council Bluffs 84
Moscow 84
Vienna 81
Shanghai 80
Da Nang 73
Milan 72
Columbus 65
Buffalo 60
Rio de Janeiro 60
Ann Arbor 59
Parma 54
Chicago 47
Naples 38
Tallinn 38
Hải Dương 37
Tashkent 34
Belo Horizonte 33
Marseille 33
Biên Hòa 32
Frankfurt am Main 32
The Dalles 32
Guangzhou 30
Tianjin 29
Toronto 29
Baghdad 28
Bologna 28
Dhaka 28
Tokyo 28
Abidjan 27
Brasília 27
Curitiba 27
Nuremberg 26
Brooklyn 25
Hefei 25
Mexico City 25
Brussels 24
Jakarta 24
London 24
Ninh Bình 24
Guayaquil 23
Medellín 23
Phoenix 23
Porto Alegre 23
Warsaw 23
Denver 22
Salvador 22
Seattle 22
Atlanta 21
Quito 21
Buenos Aires 20
Campinas 20
Fortaleza 20
Houston 20
Bremen 19
Chennai 19
Fremont 19
Seoul 19
Can Tho 18
Goiânia 18
Montreal 18
Nairobi 18
Orem 18
Pune 18
Redmond 18
Baku 17
Phủ Lý 17
Asunción 16
Bogotá 16
Caracas 16
Shenzhen 16
Amman 15
Bắc Ninh 15
Lahore 15
Manaus 15
Norwalk 15
Turin 15
Totale 14.620
Salva come PNG Salva come JPEG
Nome #
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients 241
An Impairment in Resting and Exertional Breathing Pattern May Occur in Long-Covid Patients with Normal Spirometry and Unexplained Dyspnoea 205
Distribution of the Clinical Manifestations of Alpha 1 Antitrypsin Deficiency in Respiratory Outpatients from an Area of Northern Italy 199
The COPD assessment test and the modified Medical Research Council scale are not equivalent when related to the maximal exercise capacity in COPD patients 192
Small airways in asthma: from bench-to-bedside 190
Advances in understanding of mechanisms related to increased cardiovascular risk in COPD 177
Detection of Small Airway Dysfunction in Asthmatic Patients by Spirometry and Impulse Oscillometry System 165
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: An Italian Multicenter Study 163
Coronavirus Disease 2019: COSeSco - A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae in COVID-19 Patients 154
Dexamethasone in patients hospitalized with COVID-19: Whether, when and to whom 153
Ventilation Heterogeneity in Asthma and COPD: The Value of the Poorly Communicating Fraction as the Ratio of Total Lung Capacity to Alveolar Volume 151
Detection of small airway dysfunction in asymptomatic smokers with preserved spirometry: The value of the impulse oscillometry system 148
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian Multicenter Study 146
Oral corticosteroids dependence and biologic drugs in severe asthma: Myths or facts? a systematic review of real‐world evidence 145
Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics 139
Post-COVID-19 exaggerated exertional tachycardia: Relationship with pulmonary and cardiac sequelae 133
The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma 133
Sars-cov-2 neutralizing antibodies: A network meta-analysis across vaccines 133
Breathing pattern and ventilatory response to exercise in patients with Chronic Obstructive Pulmonary Disease 132
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis 131
Clinical manifestations of a new alpha-1 antitrypsin genetic variant: Q0parma 131
A 6MWT index to predict O-2 flow correcting exercise induced SpO(2) desaturation in ILD 127
A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD 122
Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review 121
Advances with glucocorticoids in the treatment of asthma: state of the art 121
The Impact of Thermal Water in Asthma and COPD: A Systematic Review According to the PRISMA Statement 119
A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD 118
The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: A systematic review 118
The 5T approach in asthma: Triple Therapy Targeting Treatable Traits 115
Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination 115
A safety comparison of LABA plus LAMA vs LABA plus ICS combination therapy for COPD 113
Analysis of exhaled breath fingerprints and volatile organic compounds in COPD 113
Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis 112
A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study 110
A pilot survey on the quality of life in respiratory rehabilitation carried out in COPD patients with severe respiratory failure: preliminary data of a novel Inpatient Respiratory Rehabilitation Questionnaire (IRRQ) 109
Cardiovascular disease in copd 109
Corrigendum to “Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat” [Pulm. Pharmacol. Therapeut. (88), March 2025, 102342] (Pulmonary Pharmacology & Therapeutics (2025) 88, (S1094553924000580), (10.1016/j.pupt.2024.102342)) 108
Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review 108
Adding a LAMA to ICS/LABA Therapy A Meta-analysis of Triple Combination Therapy in COPD 105
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: A comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine 105
Impact of Sex on Proper Use of Inhaler Devices in Asthma and COPD: A Systematic Review and Meta-Analysis 103
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 102
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score 100
Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference 100
Clinical efficacy of inhaled corticosteroids in equine asthma: A meta-analysis and number needed to treat 99
Impact of Airway-Occluding Mucus Plugs on Mortality in Patients with COPD According to Disease Severity: A Subset Analysis of Data From COPDGene 97
Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma 97
Bayesian or frequentist: there is no question when comparing single-inhaler triple therapies via network meta-analysis. Focus on fluticasone furoate/umeclidinium/vilanterol fixed-dose combination in chronic obstructive pulmonary disease 96
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma 95
A Novel and Effective Balanced Intravenous-Inhalant Anaesthetic Protocol in Swine by Using Unrestricted Drugs 95
Can placebo challenge test (Inducing a “nocebo effect”) be a suitable model to assess stress-induced bronchial obstruction? suggestions from the multidisciplinary working groups “stress-asthma” and “AAIITO regione campania” 95
Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review 94
Face masks during COVID-19 pandemic lockdown and self-reported seasonal allergic rhinitis symptoms 94
Factors influencing the efficacy of COVID-19 vaccines: A quantitative synthesis of phase III trials 93
ACLIDINIUM/FORMOTEROL FIXED-DOSE COMBINATION FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE 92
The interplay between asthma and type 2 diabetes mellitus: mutual interactions and therapeutic implications 91
Investigational anti IL-13 asthma treatments: a 2023 update 91
Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study 91
The interplay between diabetes mellitus and chronic obstructive pulmonary disease. An overview 90
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome 90
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update 90
Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies 90
Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs 90
Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma 89
A narrative review on asthma and pest sensitization (cockroach, mouse and rat allergens): a social issue besides the medical problem 89
Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine 89
Immunoprophylaxis pharmacotherapy against canine leishmaniosis: A systematic review and meta-analysis on the efficacy of vaccines approved in European Union 89
Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short 88
Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab 88
Beyond Dual Bronchodilation - Triple Therapy, When and Why 86
Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? 86
Asthma and comorbidities: recent advances 85
Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? 84
Onset of action of budesonide/formoterol Spiromax (R) compared with budesonide/formoterol Turbuhaler (R) in patients with COPD 84
Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in real life? 84
Brensocatib: Dipeptidyl peptidase 1 (DPP1) inhibitor Treatment of non-cystic fibrosis bronchiectasis 84
Beclomethasone dipropionate and sodium cromoglycate protect against airway hyperresponsiveness in a human ex vivo model of cow's milk aspiration 84
Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: The ARCADIA study protocol 84
Asthma management with triple ICS/LABA/LAMA combination to reduce the risk of exacerbation: an umbrella review compliant with the PRIOR statement 83
Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review 83
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment 83
Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A(2)alpha for the Treatment of Asthma 82
Long-acting muscarinic antagonists under investigational to treat chronic obstructive pulmonary disease 82
Efficacy and safety of long-acting muscarinic antagonists in COPD: A meta-analysis and meta-regression with a focus on aging 81
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences 81
Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids? 81
The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review 81
Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients 81
Drug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application 80
Delivering monoclonal antibodies via inhalation: a systematic review of clinical trials in asthma and COPD 80
SMART for the treatment of asthma: A network meta-analysis of real-world evidence 80
Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses 80
Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways 80
Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile 79
Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations 79
Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review 79
Interaction between fluticasone furoate and umeclidinium in passively sensitized isolated human airways 78
Challenges in treating patients with comorbid asthma and bronchiectasis 78
Biologics for asthma and risk of pneumonia 78
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD 78
Totale 10.764
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.118 1 10 2 20 76 39 257 75 46 3 37 552
2022/20233.941 509 313 229 258 277 455 48 276 1.378 28 134 36
2023/20241.415 100 161 56 65 141 259 103 82 63 99 102 184
2024/20255.424 49 330 454 273 543 512 210 238 762 563 339 1.151
2025/202613.902 951 1.286 1.816 1.474 1.949 483 1.338 496 1.972 1.044 598 495
2026/2027116 116 0 0 0 0 0 0 0 0 0 0 0
Totale 26.215